Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

381
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
381

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prostate-Specific Antigen Screening Patterns and Metastatic Prostate Cancer in US Veterans.

JAMA network open·2026
Same author

Heterogeneous survival impact of immune-related adverse events in US veterans.

Journal for immunotherapy of cancer·2026
Same author

Maintenance Pemetrexed/Pembrolizumab Versus Pembrolizumab in Non-Small Cell Lung Cancer: A Propensity Score-Weighted Analysis.

JCO oncology practice·2026
Same author

Phenotyping Prostate Cancer in a National Health System Using Large Language Models.

JCO clinical cancer informatics·2026
Same author

Polygenic risk scores for prediction of immune checkpoint inhibitor thyroid toxicity in diverse populations.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Trial protocol: RadTARGET, a multicenter phase II randomized controlled trial evaluating focal radiotherapy boost with de-intensification of dose to non-suspicious prostate in patients with intermediate- or high-risk prostate cancer.

Clinical and translational radiation oncology·2026

Related Experiment Video

Updated: Jun 21, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.5K

Prostate-Specific Antigen Stratification for Predicting Advanced Prostate Cancer Events in Men Approaching Age Limits

Paul Riviere1,2,3, Leah N Deshler1,2,3, Kylie M Morgan1,2,3

  • 1Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California.

The Journal of Urology
|July 5, 2024
PubMed
Summary

Prostate-Specific Antigen (PSA) testing in older men (70-75) can predict metastatic or fatal prostate cancer risk. Black men have a higher risk of advanced prostate cancer than White men at similar PSA levels.

Keywords:
African Americanscancer screeninggeriatric health servicesprostate cancerprostate-specific antigen

More Related Videos

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

650
Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

21.5K

Related Experiment Videos

Last Updated: Jun 21, 2025

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.5K
Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

650
Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

21.5K

Area of Science:

  • Urology
  • Oncology
  • Geriatric Medicine

Background:

  • Prostate cancer remains a significant health concern for older men.
  • Prostate-Specific Antigen (PSA) testing is a common tool for prostate cancer screening.
  • Understanding the predictive value of PSA in older age groups is crucial for clinical decision-making.

Purpose of the Study:

  • To quantify the predictive ability of various Prostate-Specific Antigen (PSA) values for developing metastatic or fatal prostate cancer in men aged 70 to 75.
  • To assess the positive and negative predictive values of PSA testing in this demographic.

Main Methods:

  • Utilized a random sample of 80,706 men from the US Veterans Health Administration who underwent PSA testing between ages 70-75.
  • Employed cumulative/dynamic modeling to account for competing risks, such as death from non-prostate cancer causes.
  • Analyzed discriminative ability, positive predictive value, and negative predictive value at 5, 10, and 14 years post-testing.

Main Results:

  • PSA demonstrated time-dependent predictive discrimination, with Area Under the Curve (AUC) values decreasing from 0.83 to 0.73 over 14 years.
  • No statistically significant differences in predictive ability were observed based on race.
  • Black patients showed a significantly greater positive predictive value for advanced prostate cancer compared to White patients at PSA thresholds between 1-8 ng/mL.

Conclusions:

  • For men aged 70-75 with borderline-elevated PSA, the risk of developing metastatic or fatal prostate cancer is quantifiable and generally low.
  • Risk assessment for prostate cancer in this age group should consider the higher incidence observed in Black men.
  • These findings aid in informed decisions regarding the cessation of PSA testing in older men.